Form 4 Filing for Apogee Therapeutics, Inc.

This filing details transactions by Nimish P. Shah, a director at Apogee Therapeutics, Inc. (APGE), on September 3, 2026. The transactions, executed in connection with the acquisition of Apogee by AbbVie Inc., involved the disposition of 1,750,000 shares of Common Stock at $135.11 per share. Additionally, Mr. Shah disposed of 6,743,321 shares of Non-Voting Common Stock and various stock options and pre-funded warrants. These dispositions were made at a price of $135.11 per share, reflecting the merger consideration. The footnotes indicate that the reported securities were held indirectly through various Venrock entities, with disclaimers of beneficial ownership except for pecuniary interests. The transactions resulted in zero shares owned post-transaction.